Dr. Burak is a renowned endocrinologist, a member of Harvard Medical School and leader of the translational immunometabolism research group at Brigham and Women’s Hospital / Harvard Medical School. He is also a basic science researcher at the Harvard Chan School of Public Health (HSPH), Department of Molecular Metabolism. His work has been recognized with several prestigious awards, including the Early Investigators Award from The Endocrine Society. He was also selected as one of the “best doctors” of the year in the U.S. for two consecutive years (2023 and 2024) by Castle Connelly Top Doctors.
He is triple board-certified in Internal Medicine and Endocrinology, Diabetes and Metabolism (ABIM), and Obesity (ABIM). His clinical practice focuses on obesity, diabetes, parathyroid disorders, and immunometabolism.
Dr. Nils Hoem holds a Bachelor’s degree in Pharmacy, a Master’s degree, and a PhD in Pharmacology from the University of Oslo. He has many years of experience in the pharmaceutical and biotechnology industry, as well as in academic institutions.
He was a member of the Norwegian Medicines Approval Committee from 1991 to 1996, and a member of the Laboratory of Applied Pharmacokinetics at the University of Southern California, Los Angeles since the mid-1990s, and as such, has been actively involved in the research and development programs of this institution.
Dr. Hoem was also Associate Professor of Pharmacology at the University of Oslo from 1989 to 2002, and European Director of Statistics, Pharmacokinetic Modeling and Data Management at MDS Pharma Services from 2004 to 2007.
He is currently Chief Scientific Officer at Aker BioMarine in Oslo.
Prof. Dr. med. Clemens von Schacky, FESC, has been Director in the unit of Preventive Cardiology at the Ludwig Maximilians -Universität de Munich until October 2020.
Since 2007, he has been the Managing Director of the Omegametrix® fatty acid laboratory in Martinsried, a laboratory for the standardized analysis of fatty acids in red blood cells. His research has focused on aspects of cardiovascular prevention, such as omega-3 fatty acids, aspirin, ACE inhibitors, diabetes, and others (162 peer-reviewed publications in Medline).
Together with a collaborator, he invented and defined the Omega-3 Index (% EPA and DHA in red blood cells), now trademarked as the “HS-Omega-3 Index®,” supported by some 440 publications in international journals and numerous ongoing research projects.
His work has been recognized with numerous awards, including the Global Organization for EPA and DHA (GOED) Award for Global Leadership in Omega-3s in 2016.
